12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Benlysta belimumab regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said Benlysta belimumab from GlaxoSmithKline offers no additional benefit over "optimized standard therapy" for systemic lupus erythematosus (SLE) because there were no evaluable data comparing the 2 treatments....

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >